Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 11, 2006

Protherics to Take Over MacroMed

  • Protherics has acquired MacroMed in a $25-million all-stock acquisition. Protherics thus gains the company’s lead product, OncoGel, a sustained-release formulation of paclitaxel being developed for local administration in the treatment of esophageal and brain cancer. OncoGel is currently in Phase II trials.

    "The merger is very significant for MacroMed because it helps ensure that OncoGel progresses toward commercialization," says MacroMed CEO, Thomas Bergmann.

    Protherics plans to continue MacroMed operations at the current West Valley City, Ut facility. The acquisition is expected to complete in early 2007.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »